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Background
Peg in es a tide, a synthetic peptide-based erythropoiesis-stimulating agent (ESA), is a 
potential therapy for anemia in patients with advanced chronic kidney disease.
Methods
We conducted two randomized, controlled, open-label studies (EMERALD 1 and 
EMERALD 2) involving patients undergoing hemodialysis. Cardiovascular safety was 
evaluated by analysis of an adjudicated composite safety end point — death from any 
cause, stroke, myocardial infarction, or serious adverse events of congestive heart 
failure, unstable angina, or arrhythmia — with the use of pooled data from the two 
EMERALD studies and two studies involving patients not undergoing dialysis. In the 
EMERALD studies, 1608 patients received peg in es a tide once monthly or continued 
to receive epoetin one to three times a week, with the doses adjusted as necessary to 
maintain a hemoglobin level between 10.0 and 12.0 g per deciliter for 52 weeks or 
more. The primary efficacy end point was the mean change from the baseline he-
moglobin level to the mean level during the evaluation period; noninferiority was 
established if the lower limit of the two-sided 95% confidence interval was −1.0 g per 
deciliter or higher in the comparison of peg in es a tide with epoetin. The aim of 
evaluating the composite safety end point in the pooled cohort was to exclude a 
hazard ratio with peg in es a tide relative to the comparator ESA of more than 1.3.
Results
In an analysis involving 693 patients from EMERALD 1 and 725 from EMERALD 2, 
peg in es a tide was noninferior to epoetin in maintaining hemoglobin levels (mean 
between-group difference, −0.15 g per deciliter; 95% confidence interval [CI], −0.30 to 
−0.01 in EMERALD 1; and 0.10 g per deciliter; 95% CI, −0.05 to 0.26 in EMERALD 2). 
The hazard ratio for the composite safety end point was 1.06 (95% CI, 0.89 to 1.26) 
with peg in es a tide relative to the comparator ESA in the four pooled studies (2591 pa-
tients) and 0.95 (95% CI, 0.77 to 1.17) in the EMERALD studies. The proportions of 
patients with adverse and serious adverse events were similar in the treatment groups 
in the EMERALD studies. The cardiovascular safety of peg in es a tide was similar to 
that of the comparator ESA in the pooled cohort.
Conclusions
Peg in es a tide, administered monthly, was as effective as epoetin, administered one 
to three times per week, in maintaining hemoglobin levels in patients undergoing 
hemodialysis. (Funded by Affymax and Takeda Pharmaceutical; ClinicalTrials.gov 
numbers, NCT00597753 [EMERALD 1], NCT00597584 [EMERALD 2], NCT00598273 
[PEARL 1], and NCT00598442 [PEARL 2].)
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Partial correction of anemia with erythropoiesis-stimulating agents (ESAs) is a cornerstone of therapy for patients under-
going dialysis, because these agents increase he-
moglobin levels, which results in a reduction in 
blood-transfusion rates.1,2 Partial correction of ane-
mia has also been reported to enhance quality of 
life.3 More intensive treatment with ESAs, target-
ing near-normal hemoglobin levels, in the Normal 
Hematocrit Study (NHS),4 the Correction of He-
moglobin and Outcomes in Renal Insufficiency 
(CHOIR) study,5 and the Trial to Reduce Cardio-
vascular Events with Aranesp Therapy (TREAT)6 
further reduced the need for blood transfusions, 
but an increased risk of adverse events was re-
ported (the composite of death and nonfatal myo-
cardial infarction in the NHS,4 the composite of 
death and cardiovascular events in the CHOIR 
study,5 and stroke in the TREAT6). These findings 
prompted changes in the prescription information 
for ESAs, including recommendations for lower 
target hemoglobin levels and the inclusion of boxed 
warnings about increased risks associated with 
these agents.
Until recently, the ESAs that were available were 
erythropoietin analogues manufactured with the 
use of recombinant DNA technology. Most patients 
undergoing dialysis receive epoetin alfa up to three 
times a week, whereas fewer patients receive 
darbepoetin alfa once a week or every 2 weeks.7 
A continuous erythropoietin-receptor activator — 
erythropoietin attached to a polyethylene glycol 
chain8 — is an extended-dose ESA that is mar-
keted outside the United States for initial admin-
istration once every 2 weeks, with administration 
once a month after stabilization of the hemoglo-
bin level.
Peg in es a tide (Omontys, Affymax) is a synthetic, 
pegylated, peptide-based ESA that was approved 
by the Food and Drug Administration in March 
2012 for the treatment of anemia due to chronic 
kidney disease in adults undergoing dialysis. 
Peg in es a tide has no sequence homology to,9 or 
immunologic cross-reactivity with,10 erythropoi-
etin. It stimulates the erythropoietin receptor in 
vivo, thereby acting as an “epomimetic” agent. 
Previous studies have suggested that peg in es a tide 
administered once a month may be effective in 
raising and maintaining hemoglobin levels.11-13 
The current studies were designed to compare 
peg in es a tide with epoetin or darbepoetin in a pro-
spective analysis of an independently adjudicated 
composite end point for cardiovascular safety, with 
the use of pooled data from four studies: two 
involving patients undergoing hemodialysis (the 
Efficacy and Safety of Peg in es a tide for the Main-
tenance Treatment of Anemia in Patients with 
Chronic Renal Failure Who Were Receiving Hemo-
dialysis and Were Previously Treated with Epoetin 
[EMERALD] 1 and EMERALD 2 studies) and two 
involving patients not undergoing dialysis (the 
Peg in es a tide for the Correction of Anemia in Pa-
tients with Chronic Renal Failure Not on Dialysis 
and Not Receiving Treatment with Erythropoiesis-
Stimulating Agents [PEARL] 1 and PEARL 2 
studies). We present the results of the analysis of 
the efficacy and safety of peg in es a tide as com-
pared with epoetin in the cohort undergoing 
hemodialysis (the EMERALD studies cohort) and 
of the composite safety end point in the pooled 
cohort from all four studies. Data specific to the 
cohort that did not undergo dialysis (the PEARL 
studies cohort) are reported by Macdougall et al. 
elsewhere in this issue of the Journal.14
Me thods
Study Oversight
We conducted two similarly designed, phase 3, 
randomized, active-treatment–controlled, open-
label, noninferiority studies in the United States 
(EMERALD 1 and EMERALD 2) and in Europe 
(EMERALD 2). The protocol was approved by the 
institutional review board or ethics committee at 
each study site or by a central institutional review 
board. All the patients provided written informed 
consent, and the studies were performed in ac-
cordance with the International Conference on 
Harmonisation Guidelines for Good Clinical Prac-
tice. A data monitoring committee provided inde-
pendent oversight of patient safety, and a separate, 
independent event-review committee, whose mem-
bers were unaware of the treatment assignments 
and the results of hemoglobin measurements, 
adjudicated end-point events.
These studies were funded by Affymax and 
Takeda Pharmaceutical (Osaka, Japan) and were 
designed collaboratively by the principal investi-
gators (see the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org) 
and Affymax. Covance (a contract research orga-
nization) was responsible for data management; 
the statistical analyses of efficacy and safety in 
the individual studies were performed by ICON 
Clinical Research, the analyses of the composite 
safety end point were performed by Pacific North-
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSIDAD AUTONOMA DE MADRID RECTORADO on October 30, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
Peginesatide in Patients Undergoing Hemodialysis
n engl j med 368;4 nejm.org january 24, 2013 309
western Statistical Consulting, and the integrated 
analyses of efficacy and safety were performed 
by Affymax. The authors had full access to the 
data. The first author wrote the introduction and 
discussion of the manuscript and oversaw all revi-
sions; an employee of Affymax and a medical 
writer who was contracted by Affymax wrote the 
preliminary draft of the Methods and Results 
sections under the direction of the first author. 
All the authors reviewed and edited the manu-
script, vouch for the completeness and accuracy 
of the data and analyses, and testify to the fidel-
ity of this report to the study protocols, which are 
available at NEJM.org. The principal investigators 
made the decision to submit the manuscript for 
publication. Agreements between Affymax and 
the investigators stipulated that after the first 
publication of multicenter data or 36 months 
after completion of the studies, the investigators 
would be free to submit the results for publica-
tion, and Affymax could review the manuscript 
before submission.
Study Population
The first patient underwent randomization in 
September 2007, and the last patient completed 
follow-up in January 2010. Patients 18 years of 
age or older with chronic kidney disease were 
eligible if they had been undergoing hemodialysis 
for at least 3 months and had been receiving con-
tinuous epoetin treatment for at least 8 weeks. 
Other key eligibility criteria included four consec-
utive screening hemoglobin measurements with 
a mean value between 10.0 and 12.0 g per deciliter 
and at least one value for transferrin saturation 
of 20% or greater and one value for the serum 
ferritin level of 100 ng or more per milliliter. Key 
exclusion criteria were bleeding or coagulation 
disorders, hematologic diseases, or causes of ane-
mia other than chronic kidney disease; a sched-
uled kidney transplantation; poorly controlled hy-
pertension within the previous 4 weeks; red-cell 
or whole-blood transfusions within the previous 
12 weeks; and active cancer within the previous 
year (see the Supplementary Appendix).
Study Procedures
Each study included a 6-week screening period, a 
28-week initial dose-adjustment period, an 8-week 
evaluation period, and a longer-term follow-up 
period (≥16 additional weeks). Eligible patients 
were randomly assigned, in a 2:1 ratio, to receive 
peg in es a tide once every 4 weeks or to continue to 
receive epoetin (epoetin alfa in the United States, 
and epoetin beta in Europe) one to three times a 
week, with the frequency and route of adminis-
tration determined on the basis of the treatment 
regimen during the screening period; peg in es a tide 
and epoetin were administered intravenously in 
the EMERALD 1 study and intravenously or subcu-
taneously in the EMERALD 2 study. In both stud-
ies, sequential randomization was performed at a 
central location and was stratified according to the 
mean screening hemoglobin level (≤11.4 g per deci-
liter vs. ≥11.5 g per deciliter), to ensure balance in 
baseline efficacy variables, and according to the 
New York Heart Association heart failure class 
(no heart failure or class I vs. class II, III, or IV), 
to help ensure balance in baseline cardiovascular 
risk.15 In the EMERALD 2 study, randomization 
was also stratified according to geographic region 
and according to the route of study-drug admin-
istration.
Patients who were randomly assigned to the 
peg in es a tide group underwent a 1-week transition 
period during which they received no epoetin and 
after which they began receiving peg in es a tide, 
with the dose determined according to the last 
total weekly weight-based dose of epoetin that 
they had received during the screening period 
(Table S1 in the Supplementary Appendix). Pa-
tients who were assigned to the epoetin group 
continued to receive epoetin according to their 
regimen during the screening period. Subsequent 
doses (not weight-based) of both study medica-
tions were adjusted according to prespecified 
guidelines to maintain the hemoglobin level 
between 10.0 and 12.0 g per deciliter (Table S2 
in the Supplementary Appendix).
Blood chemical measurements were performed 
at a central laboratory. Hemoglobin measurements 
were performed at the time of screening, at 
baseline, and weekly (during the evaluation pe-
riod and during delays in dosing owing to a high 
hemoglobin level) or every 2 weeks (during all 
other periods) thereafter. At each visit, informa-
tion was obtained on adverse events, transfusions, 
the need for therapeutic phlebotomies, and the use 
of concomitant medications.
Study End Points
The primary efficacy end point was the mean 
change from the baseline hemoglobin level (with 
the baseline level calculated as the mean of four 
consecutive measurements during the screening 
period and the value on the day of randomiza-
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tion) to the mean level during the evaluation pe-
riod (calculated as the mean of all measurements 
obtained during weeks 29 through 36) (see the 
Supplementary Appendix). Secondary efficacy end 
points were the proportion of patients who re-
ceived a transfusion during the initial dose- 
adjustment period and during the evaluation pe-
riod and the proportion of patients in whom the 
hemoglobin level was maintained within the tar-
get range during the evaluation period. Efficacy 
was also assessed as the mean change from base-
line in hemoglobin levels during 4-week intervals. 
The analysis of adverse events was performed 
with pooled data from the two EMERALD stud-
ies to provide a larger data set for evaluation (see 
the Supplementary Appendix). Data on immuno-
genicity are presented for patients who were re-
ceiving peg in es a tide.
Cardiovascular risk was assessed by means of 
a prospectively planned analysis of a composite 
safety end point: death from any cause, stroke, 
myocardial infarction, or a serious adverse event 
of congestive heart failure, unstable angina, or 
arrhythmia. The processes of identification and 
assessment of potential events were prespecified 
and were designed to ensure that the treatment 
assignments and hemoglobin levels remained con-
cealed and to minimize bias (see the Supplemen-
tary Appendix). The prespecified primary analy-
sis of the composite safety end point assessed 
the time to the first positively adjudicated event, 
with the use of data pooled from the EMERALD 1 
and EMERALD 2 studies and also from the 
PEARL 1 and PEARL 2 studies, two parallel stud-
ies comparing peg in es a tide and darbepoetin in 
patients with chronic kidney disease who were not 
undergoing dialysis. Prespecified analyses ac-
cording to population (patients undergoing he-
modialysis and patients not undergoing dialysis) 
were performed; results in the population not 
undergoing dialysis are reported separately.14
Statistical Analysis
The primary-analysis population for the assess-
ment of safety comprised all patients who under-
went randomization and who received at least 
one dose of the study drug (i.e., the modified 
intention-to-treat population). Patient data were 
summarized according to the assigned study 
treatment. The primary efficacy analysis includ-
ed patients in the primary-analysis population 
who also had at least one hemoglobin measure-
ment during the evaluation period. There was no 
imputation of missing data in the primary effi-
cacy analyses.
The primary efficacy end point was analyzed 
with the use of an analysis-of-variance cell means 
model to estimate the mean change from the base-
line hemoglobin level to the mean level during the 
evaluation period within each randomization stra-
tum. Estimates of the difference in the primary 
efficacy end point between the peg in es a tide group 
and the epoetin group and corresponding two-
sided 95% confidence intervals were calculated 
with the use of the analysis-of-variance model. 
Treatment differences were calculated for each of 
the strata and then these stratum-specific esti-
mates of treatment difference were combined 
with the use of weights proportional to the total 
sample size of the stratum. Because there was 
no imputation of missing data, prespecified per-
protocol population analyses and sensitivity anal-
yses with imputation of missing values were 
performed to address the potential effects of pre-
mature withdrawal from the studies (see the Sup-
plementary Appendix).
Each study had at least 99% power to evaluate 
the noninferiority of peg in es a tide to epoetin with 
respect to the primary efficacy end point, as-
suming an expected mean (±SD) between-group 
difference in hemoglobin level of 0±1.5 g per 
deciliter. Noninferiority was established if the 
lower limit of the two-sided 95% confidence in-
tervals for the least-squares mean difference 
between peg in es a tide and epoetin was −1.0 g per 
deciliter or higher. The Cochran–Mantel–Haenszel 
method was used for the secondary end-point 
analyses. The efficacy variables for each study are 
presented separately.
For the primary analysis of the composite 
safety end point, we estimated that if 553 patients 
had a positively adjudicated event, the pooled data 
would provide at least 89% power to exclude a 
hazard ratio with peg in es a tide relative to the com-
parator ESA of more than 1.3, with the use of a 
one-sided 95% confidence interval (see the Supple-
mentary Appendix).4,5,16 The studies were event-
driven; patients continued to receive the assigned 
treatment until the prespecified number of posi-
tively adjudicated events across all four studies was 
reached (with a minimum anticipated follow-up of 
at least 52 weeks). Patients who discontinued the 
study drug prematurely remained in the studies 
and were followed to ensure complete recording 
of safety events. Hazard ratios were estimated for 
each study and were combined with the use of 
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weights inversely proportionate to the variance; 
a one-sided 95% confidence interval was desig-
nated for the primary analysis, and two-sided 
95% confidence intervals for the secondary analy-
ses. The Kaplan–Meier method was used to char-
acterize the time to the first event. Analyses of the 
composite rate of major adverse cardiovascular 
events (death from any cause, stroke, or myocar-
dial infarction) were also performed.
To determine the influence of events occur-
ring after discontinuation of the study drug, a 
prespecified sensitivity analysis of the composite 
safety end point was performed in which data 
were censored 28 days after a patient received 
the last dose of the study drug, initiated treat-
ment with a non-study ESA, or underwent renal 
transplantation, whichever occurred first. A post 
hoc sensitivity analysis addressed the influence 
of withdrawals from the studies (see the Supple-
mentary Appendix).
R esult s
Study Patients
In the EMERALD 1 study, 803 patients under-
went randomization at 92 sites in the United 
States, and in the EMERALD 2 study, 823 pa-
tients underwent randomization at 39 sites in the 
United States and 47 sites in Europe. The primary-
analysis population comprised 793 patients in the 
EMERALD 1 study (of whom 524 were assigned 
to receive peg in es a tide and 269 were assigned to 
receive epoetin, with both drugs administered 
intravenously in all patients) and 815 patients in 
the EMERALD 2 study (of whom 542 were as-
signed to receive peg in es a tide [437 intravenously 
and 105 subcutaneously] and 273 were assigned 
to received epoetin [220 intravenously and 53 
subcutaneously]). A total of 225 patients in the 
EMERALD 1 study (158 [30.2%] in the peg in es a-
tide group and 67 [24.9%] in the epoetin group) 
and 183 patients in the EMERALD 2 study (121 
[22.3%] in the peg in es a tide and 62 [22.7%] in the 
epoetin group) discontinued the study prema-
turely; the most common reasons for discontinu-
ation were death and withdrawal of consent; 
other common reasons included relocation, site 
closure, and renal transplantation (Fig. 1).
Overall, the groups were well matched at base-
line (Table 1, and Table S3 in the Supplementary 
Appendix). The mean baseline hemoglobin level 
in both groups was 11.3 g per deciliter in the 
EMERALD 1 cohort and 11.2 g per deciliter in 
the EMERALD 2 cohort. In both studies, the 
iron status was similar in the two groups. The 
peg in es a tide group had higher rates of coronary 
artery disease (in the EMERALD 1 study) and 
arrhythmia (in the EMERALD 2 study).
The median duration of follow-up was 67.4 
weeks (interquartile range, 60.0 to 77.1) in the 
peg in es a tide group and 68.1 weeks (interquartile 
range, 60.1 to 78.6) in the epoetin group in the 
EMERALD 1 study and 65.1 weeks (interquartile 
range, 57.9 to 75.1) in the peg in es a tide group 
and 64.1 weeks (interquartile range, 58.3 to 74.9) 
in the epoetin group in the EMERALD 2 study 
(see the Supplementary Appendix for informa-
tion on patient exposure). The median of the 
mean dose per patient administered during the 
evaluation period was 5.7 mg of peg in es a tide per 
injection and 9900 U of epoetin per week in the 
EMERALD 1 cohort and 4.8 mg of peg in es a tide 
per injection (with both intravenous and subcu-
taneous injections) and 6805 U of epoetin per 
week (7100 U per week for intravenous injec-
tions and 4625 U per week for subcutaneous 
injections) in the EMERALD 2 cohort.
Primary Efficacy End Point
The primary efficacy analysis (which included 
data only from patients who had at least one he-
moglobin measurement during the evaluation 
period) included data from 693 patients (87.4% of 
the patients in the primary-analysis population) 
in the EMERALD 1 study (445 [84.9%] in the 
peg in es a tide group and 248 [92.2%] in the epoetin 
group) and 725 patients (89.0% of the patients in 
the primary-analysis population) in the EMERALD 
2 study (488 [90.0%] in the peg in es a tide group 
and 237 [86.8%] in the epoetin group). The mean 
changes from the baseline hemoglobin level to the 
mean level during the evaluation period were 
−0.24±0.96 g per deciliter in the peg in es a tide 
group and −0.09±0.92 g per deciliter in the epo-
etin group in the EMERALD 1 study and 
−0.07±1.01 g per deciliter in the peg in es a tide 
group and −0.17±1.00 g per deciliter in the epo-
etin group in the EMERALD 2 study. In both 
studies, the prespecified noninferiority criterion 
was met: the least-squares mean difference be-
tween the groups was −0.15 g per deciliter (95% 
confidence interval [CI], −0.30 to −0.01) in the 
EMERALD 1 study and 0.10 g per deciliter (95% 
CI, −0.05 to 0.26) in the EMERALD 2 study. The 
results of all per-protocol and sensitivity analyses 
were consistent with the primary efficacy results.
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Secondary and Other Efficacy End Points
The proportion of patients who received at least 
one transfusion during the initial dose-adjustment 
period and the evaluation period was similar in 
the two treatment groups: 10.3% in the peg in es-
a tide group and 8.6% in the epoetin group in the 
EMERALD 1 study (relative risk with peg in es a-
tide, 1.21; 95% CI, 0.76 to 1.92) and 7.7% and 9.9% 
in the two groups, respectively, in the EMERALD 
2 study (relative risk, 0.79; 95% CI, 0.50 to 1.24). 
The proportion of patients in whom the mean 
hemoglobin concentration was maintained with-
in the target range during the evaluation period 
was 63.0% in the peg in es a tide group and 71.7% 
in the epoetin group in the EMERALD 1 study 
(relative response rate with peg in es a tide, 0.88; 
95% CI, 0.79 to 0.97) and 63.5% and 65.9% in the 
EMERALD 2 study (relative response rate with 
peg in es a tide, 0.96; 95% CI, 0.87 to 1.07) (see the 
Supplementary Appendix for more details re-
garding the analysis of response rate). In both 
studies, the iron status at the end of the evalua-
tion period and the percentage of patients receiv-
ing iron supplementation during the study were 
generally similar in the two groups (Table S4 in 
the Supplementary Appendix). The mean hemo-
globin values in 4-week intervals were similar in 
the two groups and were within the target range 
in the two groups in both studies (Fig. 2).
Adverse Events
In the EMERALD studies, the proportion of pa-
tients in whom an adverse event was reported was 
similar in the peg in es a tide group and the epoetin 
group (94.6% and 93.0%, respectively), with no 
major between-group differences (i.e., differenc-
es of ≥5 percentage points in the rates of indi-
vidual events [Table S5 in the Supplementary Ap-
pendix]). Serious adverse events were reported in 
572 patients (53.7%) in the peg in es a tide group 
and 309 (57.0%) in the epoetin group; the serious 
adverse events that occurred in at least 3% of the 
patients in either group are shown in Table 2. 
There were no clinically relevant between-group 
differences in the incidence of adverse events as-
sociated with the ESA class of drugs, including 
hypertension-related and thromboembolic events 
(Table 2). There was no evidence of drug-induced 
hepatotoxic effects with either drug, and other 
data on clinical laboratory results and vital signs 
suggested no major differences between the 
groups.
Across the two EMERALD studies, 22.2% of 
the patients in the peg in es a tide group and 19.6% 
of those in the epoetin group had confirmed 
(i.e., two consecutive) hemoglobin measurements 
that were higher than 13 g per deciliter through 
the end of treatment (Table S6 in the Supplemen-
tary Appendix). Ten patients — seven (0.7%) in 
the peg in es a tide group and three (0.6%) in the 
epoetin group — underwent at least one thera-
peutic phlebotomy.
Immunogenicity of Peg in es a tide
Drug-specific binding antibodies developed in 12 
patients (1.1%) in the peg in es a tide groups (6 in 
each study); in 8 patients, the antibodies were 
neutralizing in an in vitro assay. Ten of the 12 
patients (including the 8 patients with neutraliz-
ing antibodies) had at least two clinical signs of 
Figure 1 (facing page). Screening, Randomization, 
and Follow-up.
Two similarly designed studies involving patients under-
going hemodialysis were conducted: the Efficacy and 
Safety of Peg in es a tide for the Maintenance Treatment 
of Anemia in Patients with Chronic Renal Failure Who 
Were Receiving Hemodialysis and Were Previously 
Treated with Epoetin (EMERALD) 1 study (Panel A) 
and the EMERALD 2 study (Panel B). Patients who dis-
continued the study drug remained in the study for the 
collection of data relevant to the composite safety end 
point. Thus, discontinuing the study drug was distinct 
from discontinuing the study, and separate reasons for 
each were recorded and summarized. In the EMERALD 1 
study, the study drug was not administered to 8 patients 
randomly assigned to the peg in es a tide group and 2 pa-
tients assigned to the epoetin group. The reasons for 
premature discontinuation of the study drug in the 
peg in es a tide group were adverse events (20 patients), 
lack of efficacy (1), renal transplantation (3), withdrawal 
of consent for study treatment (2), change to peritoneal 
dialysis (2), nonadherence to the protocol (1), investi-
gator’s decision (1), and relocation (2). The reasons  
for premature discontinuation of the study drug in the 
epoetin group were renal transplantation (5 patients) 
and withdrawal of consent for study treatment (1). In 
the EMERALD 2 study, the study drug was not admin-
istered to 7 patients randomly assigned to the peg in es-
a tide group and 1 patient assigned to the epoetin group. 
The reasons for premature discontinuation of the study 
drug in the peg in es a tide group were adverse events  
(2 patients), lack of efficacy (1), renal transplantation 
(6), withdrawal of consent for study treatment (4), inves-
tigator’s decision (1), and relocation (4). The reasons 
for premature discontinuation of the study drug in the 
epoetin group were renal transplantation (3 patients), 
withdrawal of consent for study treatment (1), and  
relocation (5).
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possible reduced efficacy (declining hemoglobin 
levels, the need for increased doses to maintain 
hemoglobin levels, or the need for transfusion 
that was not explained by a concurrent acute 
medical event). No cases of pure red-cell aplasia 
were reported, and antierythropoietin antibodies 
did not develop in any patient. No patient had an 
allergic drug reaction, including anaphylaxis, as-
sociated with the formation of antibodies.
Composite Safety End Point
In the combined phase 3 studies (EMERALD 1, 
EMERALD 2, PEARL 1, and PEARL 2), a total of 
1737 patients were randomly assigned to receive 
peg in es a tide and 872 to receive the comparator 
ESA. Of these patients, 1722 and 869 in the two 
groups, respectively, received at least one dose of 
the study drug and were included in the pooled 
analysis of the composite safety end point. The 
proportion of patients with unknown vital status 
was low overall (4.1%) and was similar in the two 
groups (see the Supplementary Appendix).
In the pooled analysis of data from the four 
studies, a composite safety end-point event oc-
curred in 384 patients (22.3%) who received peg-
in es a tide and in 188 patients (21.6%) who re-
ceived the comparator ESA (hazard ratio with 
peg in es a tide, 1.06; 95% CI, 0.89 to 1.26) (Fig. 3A). 
The results in the cohort that was undergoing 
hemodialysis (patients in the EMERALD studies) 
indicated a similar cardiovascular safety profile: 
a hazard ratio with peg in es a tide relative to epo-
Table 1. Baseline Demographic and Clinical Characteristics in the EMERALD 1 and EMERALD 2 Studies.*
Characteristic EMERALD 1 EMERALD 2
Peg in es a tide
(N = 524)
Epoetin
(N = 269) P Value†
Peg in es a tide
(N = 542)
Epoetin
(N = 273) P Value†
Age — yr 57.3±14.0 57.5±13.7 0.86 58.8±14.5 58.6±13.7 0.83
Male sex — no. (%) 293 (55.9) 144 (53.5) 0.52 331 (61.1) 153 (56.0) 0.18
Race — no. (%)‡ 0.15 0.37
White 263 (50.2) 116 (43.1) 354 (65.3) 183 (67.0)
Black 234 (44.7) 136 (50.6) 165 (30.4) 75 (27.5)
Hemoglobin — g/dl 11.3±0.5 11.3±0.5 NA§ 11.2±0.6 11.2±0.6 NA§
Primary cause of chronic kidney disease  
— no. (%) 0.82 0.15
Diabetes 222 (42.4) 118 (43.9) 174 (32.1) 96 (35.2)
Hypertension 184 (35.1) 97 (36.1) 155 (28.6) 57 (20.9)
Undergoing hemodialysis >1 yr — no. (%) 475 (90.6) 237 (88.1) 0.27 460 (84.9) 233 (85.3) 0.87
NYHA class — no. (%) NA§ NA§
No heart failure or class I 426 (81.3) 217 (80.7) 438 (80.8) 223 (81.7)
Class II, III, or IV 98 (18.7) 52 (19.3) 104 (19.2) 50 (18.3)
History of cardiovascular risk factors  
— no. (%)
Diabetes 298 (56.9) 151 (56.1) 0.84 238 (43.9) 124 (45.4) 0.67
Coronary artery disease 238 (45.4) 100 (37.2) 0.02 209 (38.6) 91 (33.3) 0.13
Peripheral vascular disease 145 (27.7) 70 (26.0) 0.59 112 (20.7) 49 (17.9) 0.36
Arrhythmia 102 (19.5) 65 (24.2) 0.12 122 (22.5) 40 (14.7) 0.007
* Plus–minus values are means ±SD. A more detailed listing of baseline variables is provided in Table S3 in the Sup ple-
mentary Appendix; none of the additional variables listed in Table S3 differed significantly between treatment groups in 
either study. EMERALD denotes Efficacy and Safety of Peg in es a tide for the Maintenance Treatment of Anemia in Patients 
with Chronic Renal Failure Who Were Receiving Hemodialysis and Were Previously Treated with Epoetin, NA not available, 
and NYHA New York Heart Association.
† P values were calculated with the use of analysis of variance for continuous variables and the Mantel–Haenszel chi-square 
test for categorical variables, with adjustment for stratification factors.
‡ Race was determined from information in the case-report form.
§ Statistical tests were not performed on stratification factors.
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etin of 0.95 (95% CI, 0.77 to 1.17) (Fig. 3B). 
There were no apparent between-group differ-
ences in the proportion of patients with events 
of the individual components of the safety end 
point (including death), either in the pooled co-
hort from all four studies (Table S7 and Fig. S1 
in the Supplementary Appendix) or in the cohort 
that was undergoing hemodialysis (Table 2, and 
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Figure 2. Mean Hemoglobin Level, According to Study Week.
Data are shown for patients in the EMERALD 1 study (Panel A) and the EMERALD 2 study (Panel B). Dashed vertical 
lines indicate the evaluation period (weeks 29 to 36). Horizontal solid lines indicate the target range for the hemo-
globin level (10 to 12 g per deciliter). I bars indicate standard errors.
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Table 2. Component Events of the Composite Safety End Point, Most Common Serious Adverse Events, and Adverse 
Events Associated with the Erythropoiesis-Stimulating Agent (ESA) Class of Drugs.*
Event
Peg in es a tide
(N = 1066)
Epoetin
(N = 542)
no. of patients (%)
Component event of the composite safety end point†
Death 115 (10.8) 64 (11.8)
Cardiovascular 31 (2.9) 14 (2.6)
Noncardiovascular 43 (4.0) 24 (4.4)
Sudden‡ 26 (2.4) 12 (2.2)
Unknown cause§ 15 (1.4) 14 (2.6)
Stroke 26 (2.4) 20 (3.7)
Myocardial infarction 49 (4.6) 29 (5.4)
Congestive heart failure 103 (9.7) 49 (9.0)
Unstable angina 24 (2.3) 12 (2.2)
Arrhythmia 63 (5.9) 35 (6.5)
Serious adverse event occurring in ≥3% of patients in either group¶
Congestive cardiac failure 61 (5.7) 37 (6.8)
Acute myocardial infarction 30 (2.8) 18 (3.3)
Pneumonia 67 (6.3) 31 (5.7)
Sepsis 35 (3.3) 26 (4.8)
Cellulitis 34 (3.2) 15 (2.8)
Fluid overload 41 (3.8) 27 (5.0)
Hyperkalemia 49 (4.6) 23 (4.2)
Respiratory failure 32 (3.0) 12 (2.2)
Adverse-event category associated with the ESA class of drugs‖
Hypertension-related events 208 (19.5) 101 (18.6)
Thromboembolic events
Arterial event 71 (6.7) 48 (8.9)
Venous event 21 (2.0) 9 (1.7)
Complication related to vascular access 193 (18.1) 107 (19.7)
Convulsions 23 (2.2) 11 (2.0)
Infusion or injection-related reactions 32 (3.0) 11 (2.0)
Cancer 41 (3.8) 23 (4.2)
* Data are pooled from the EMERALD 1 and EMERALD 2 studies.
† Component events of the composite safety end point were adjudicated by an independent event-review committee 
whose members were unaware of the treatment assignments and hemoglobin levels; patients could have more than 
one event.
‡ Sudden death was defined as nontraumatic or unexpected death within 1 hour after the onset of symptoms or unwit-
nessed death.
§ The cause of death was classified as unknown if the primary cause could not be determined, including those cases in 
which there was insufficient information.
¶ There were no major differences (i.e., differences of ≥2 percentage points) between the pooled peg in es a tide and epoetin 
groups with respect to serious adverse events, including those that were reported at a frequency of less than 3% in either 
group.
‖ Categories of adverse events associated with the ESA class of drugs were identified from the Medical Dictionary for 
Regulatory Activities (MedDRA) with the use of the Standardized MedDRA Query (SMQ); however, in the case of infu-
sion or injection-related reactions and complications related to vascular access, for which there are no suitable SMQs 
in MedDRA, the categories were identified according to sponsor-defined groups of preferred terms. This approach en-
abled the grouping of similar or related events that embodied similar clinical concepts. The proportion of patients re-
porting adverse events was similar in the pooled peg in es a tide and epoetin groups (94.6% and 93.0%, respectively), 
with no major between-group differences (≥5 percentage points) in any individual event.
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Fig. S1 in the Supplementary Appendix). Mortality 
among the patients undergoing hemodialysis was 
similar in the peg in es a tide and epoetin groups 
(hazard ratio for death, 0.90; 95% CI, 0.67 to 
1.23). Results for the composite safety end point 
in subgroups defined according to baseline vari-
ables (e.g., black vs. nonblack race and presence vs. 
absence of diabetes) were consistent with those in 
the overall population undergoing hemodialysis 
(Fig. S2 in the Supplementary Appendix). The sen-
sitivity analysis addressing the potential effect of 
withdrawals from the studies showed results simi-
lar to those of the primary analysis (see the Sup-
plementary Appendix). Hazard ratios for major 
adverse cardiovascular events among patients still 
in the studies (“on-study” analysis) and among 
patients still receiving the study drug (“on-drug” 
analysis), as estimated in sensitivity analyses, are 
shown in Figure S3 in the Supplementary Appen-
dix. The hazard ratio for death with peg in es a tide 
relative to epoetin in the on-drug analysis was 
0.57 (95% CI, 0.38 to 0.85).
Discussion
We studied the efficacy and cardiovascular safety 
of peg in es a tide as compared with other ESAs, us-
ing the target hemoglobin level (10 to 12 g per 
deciliter in the EMERALD studies) that was the 
standard when the trials were conducted. For the 
assessment of cardiovascular safety, composite 
safety end-point events were adjudicated by an 
independent event-review committee whose mem-
bers were unaware of the group assignments and 
hemoglobin levels.
Among patients undergoing hemodialysis 
(those in the EMERALD 1 and EMERALD 2 stud-
ies), peg in es a tide administered once a month was 
as effective as epoetin administered one to three 
times a week in maintaining hemoglobin levels. 
Rates of confirmed hemoglobin excursions and 
transfusions were similar in the two groups.
Adverse (including serious adverse) events in 
the EMERALD studies were similar in the peg-
in es a tide and epoetin groups and were consistent 
with expected adverse events in patients undergo-
ing hemodialysis. No between-group differences 
were observed in the rate of events associated 
with the ESA class of drugs, including venous 
thromboembolic events, complications related to 
hemodialysis access, hypertension-related events, 
and cancer.
In the analysis of the composite safety end 
point with the use of data pooled from the two 
EMERALD studies and the two PEARL studies, 
the incidence of events was similar in the group 
receiving peg in es a tide and the group receiving 
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Figure 3. Kaplan–Meier Curves for the Event-free Rate of the Composite 
Safety End Point.
The curves illustrate the proportion of patients at each time point who had 
not had any of the following events: death from any cause, stroke, myocardi-
al infarction, or a serious adverse event of congestive heart failure, unstable 
angina, or arrhythmia (all of which are components of the composite safety 
end point). Panel A shows data for this end point in the pooled analysis of 
four phase 3 studies: EMERALD 1 and EMERALD 2 plus the Peg in es a tide for 
the Correction of Anemia in Patients with Chronic Renal Failure Not on Dial-
ysis and Not Receiving Treatment with Erythropoiesis-Stimulating Agents 
(PEARL) 1 and PEARL 2 studies, which involved patients who were not  
undergoing dialysis. Panel B shows data for the composite safety end point 
in the analysis of data only from patients undergoing hemodialysis (the  
EMERALD 1 and EMERALD 2 studies).
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the comparator ESAs. Among the patients un-
dergoing hemodialysis (patients in the EMERALD 
studies), the occurrence of the composite safety 
end point was similar in the two groups; the 
point estimate was approximately 1 and was con-
sistent across patient subgroups.
Peg in es a tide-specific neutralizing antibodies 
developed in eight patients; antierythropoietin 
antibodies did not develop in any patients, and 
no pure red-cell aplasia cases were reported. Ac-
cording to a previous report of an ongoing study, 
peg in es a tide was used to treat a small cohort of 
patients with chronic kidney disease who had 
pure red-cell aplasia and antierythropoietin anti-
bodies, most of whom were transfusion-depen-
dent.17 Longer-term follow-up of patients is war-
ranted to further evaluate the immunogenicity 
profile of peg in es a tide, including the incidence 
of antibody formation and potential clinical 
consequences.
There are several limitations of these studies. 
First, in the composite safety end point that was 
used to assess cardiovascular risk, we included 
“softer” end points such as arrhythmia, conges-
tive heart failure, and unstable angina. Although 
end points were adjudicated by an event-review 
committee whose members were unaware of the 
group assignments and who used criteria widely 
used in other trials with cardiovascular outcomes, 
including trials of ESAs, adjudicating events such 
as congestive heart failure in a population with 
anuria that is prone to frequent episodes of vol-
ume overload and flash pulmonary edema is dif-
ficult. The results of an evaluation of the more 
definite end points of death (including sudden 
death), myocardial infarction, and stroke were 
consistent with the overall hemodialysis findings.
A second limitation of the studies was the 
open-label design. However, efforts were made 
to minimize potential bias, including concealing 
the group assignments and the hemoglobin con-
centrations from the members of the event- 
review committee and prospectively defining an 
investigator-independent process for identifying 
potential events for adjudication. Third, the 
number of premature withdrawals may have in-
fluenced the results. However, analyses of the 
per-protocol population (for efficacy) and sensi-
tivity analyses (for efficacy and safety) showed 
results consistent with those of the primary 
analyses. Fourth, the EMERALD studies used a 
hemoglobin target (10 to 12 g per deciliter) that 
was consistent with clinical practice guidelines 
at the time the studies were conducted. Current 
U.S. labels on ESAs recommend reducing or in-
terrupting ESA treatment if the hemoglobin level 
approaches or exceeds 11 g per deciliter. How-
ever, since the dose of peg in es a tide can be ad-
justed,12,13 it seems unlikely that lower targets 
would have led to clinically relevant differences 
between the agents.
In conclusion, peg in es a tide, administered once 
a month, was similar to epoetin, administered 
one to three times a week, for the treatment of 
anemia in patients receiving hemodialysis.
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